Cincinnati Children’s

Hippocratic AI focuses on developing safety-oriented large language models specifically designed for non-diagnostic, patient-facing applications in healthcare. Unlike conventional models that are often trained on diverse internet data, which may include unreliable information, Hippocratic AI emphasizes the acquisition of evidence-based healthcare content through lawful channels. The company aims to enhance healthcare accessibility and outcomes by creating a platform that facilitates safe artificial health general intelligence. This innovation seeks to empower patients to manage their health more effectively from home, thereby improving overall health outcomes with minimal inconvenience.

STAQ Pharma, Inc. is a Denver-based company that specializes in manufacturing and selling compounded pharmaceutical medications. Founded in 2018, it operates a current Good Manufacturing Practice (cGMP) outsourcing facility that produces a range of compounded medications, including sterile solutions and prefilled syringes for hospital procedures. The company emphasizes safety, quality, and transparency in its offerings, providing healthcare facilities with reliable access to these critical products. STAQ Pharma sells its medications through its own pharmaceutical facilities and an online store, ensuring that inventory systems are in place to forecast needs and proactively supply partners with essential medications.

Enable Injections, LLC specializes in the design and manufacture of disposable, body-worn bolus injectors that facilitate the delivery of high viscosity and volume injectable drugs directly into subcutaneous tissue. Established in 2010 and based in Cincinnati, Ohio, the company’s innovative devices can utilize standard containers such as vials, syringes, or cartridges. These injectors not only allow for the reconstitution of powdered drugs but also enable the delivery of up to 20 ml of medication. The system automatically warms and mixes lyophilized solutions, ensuring a seamless injection experience. Additionally, Enable Injections offers a version of its platform that can connect to smartphones via Bluetooth, enhancing user interaction. With approximately 900 new drugs in development that may benefit from this technology, the market for bolus injection systems is projected to reach $8 billion within the next decade.

Airway Therapeutics, Inc. is a biopharmaceutical company focused on developing protein therapeutics for lung and pediatric applications. Based in Cincinnati, Ohio, with additional offices in Marietta, Georgia, the company specializes in products like recombinant human surfactant protein-D, aimed at preventing bronchopulmonary dysplasia in premature infants, and AT100, a protein replacement therapy for the same condition. The company licenses technology from the pulmonary research program of Cincinnati Children's Hospital Medical Center, which supports the development of multiple products targeting various lung disorders. Airway Therapeutics aims to address the cycle of injury and inflammation in patients with respiratory and inflammatory diseases through advanced biologics that reduce inflammation, infection, and modulate immune responses, ultimately improving treatment outcomes.

Enable Injections, LLC specializes in the design and manufacture of disposable, body-worn bolus injectors that facilitate the delivery of high viscosity and volume injectable drugs directly into subcutaneous tissue. Established in 2010 and based in Cincinnati, Ohio, the company’s innovative devices can utilize standard containers such as vials, syringes, or cartridges. These injectors not only allow for the reconstitution of powdered drugs but also enable the delivery of up to 20 ml of medication. The system automatically warms and mixes lyophilized solutions, ensuring a seamless injection experience. Additionally, Enable Injections offers a version of its platform that can connect to smartphones via Bluetooth, enhancing user interaction. With approximately 900 new drugs in development that may benefit from this technology, the market for bolus injection systems is projected to reach $8 billion within the next decade.

Airway Therapeutics, Inc. is a biopharmaceutical company focused on developing protein therapeutics for lung and pediatric applications. Based in Cincinnati, Ohio, with additional offices in Marietta, Georgia, the company specializes in products like recombinant human surfactant protein-D, aimed at preventing bronchopulmonary dysplasia in premature infants, and AT100, a protein replacement therapy for the same condition. The company licenses technology from the pulmonary research program of Cincinnati Children's Hospital Medical Center, which supports the development of multiple products targeting various lung disorders. Airway Therapeutics aims to address the cycle of injury and inflammation in patients with respiratory and inflammatory diseases through advanced biologics that reduce inflammation, infection, and modulate immune responses, ultimately improving treatment outcomes.

Airway Therapeutics, Inc. is a biopharmaceutical company focused on developing protein therapeutics for lung and pediatric applications. Based in Cincinnati, Ohio, with additional offices in Marietta, Georgia, the company specializes in products like recombinant human surfactant protein-D, aimed at preventing bronchopulmonary dysplasia in premature infants, and AT100, a protein replacement therapy for the same condition. The company licenses technology from the pulmonary research program of Cincinnati Children's Hospital Medical Center, which supports the development of multiple products targeting various lung disorders. Airway Therapeutics aims to address the cycle of injury and inflammation in patients with respiratory and inflammatory diseases through advanced biologics that reduce inflammation, infection, and modulate immune responses, ultimately improving treatment outcomes.

Enable Injections, LLC specializes in the design and manufacture of disposable, body-worn bolus injectors that facilitate the delivery of high viscosity and volume injectable drugs directly into subcutaneous tissue. Established in 2010 and based in Cincinnati, Ohio, the company’s innovative devices can utilize standard containers such as vials, syringes, or cartridges. These injectors not only allow for the reconstitution of powdered drugs but also enable the delivery of up to 20 ml of medication. The system automatically warms and mixes lyophilized solutions, ensuring a seamless injection experience. Additionally, Enable Injections offers a version of its platform that can connect to smartphones via Bluetooth, enhancing user interaction. With approximately 900 new drugs in development that may benefit from this technology, the market for bolus injection systems is projected to reach $8 billion within the next decade.

Claritas Genomics, Inc. is a genetic diagnostic testing laboratory based in Cambridge, Massachusetts, specializing in services for pediatric disorders. Established in 2012 as a subsidiary of The Children's Hospital Corporation, the company focuses on providing a comprehensive range of genetic testing, including clinical exome analysis, single gene sequencing, and assay analysis for gene deletions and duplications. It utilizes advanced instrumentation and bioinformatics, combining these with clinical expertise from specialists at Boston Children's Hospital, a leading pediatric institution. The laboratory aims to simplify the selection of molecular tests and supports clinicians in navigating the complexities of genetic diagnostics. Its interpretive services ensure that reports convey intricate genetic information clearly, aiding in informed medical decision-making.

AssureRX Health is a personalized medicine company based in Mason, Ohio, specializing in pharmacogenomics. The company aims to assist healthcare providers in identifying the most suitable medications for individual patients suffering from neuropsychiatric and chronic pain conditions. By offering treatment decision support, AssureRX Health enables clinicians to collect and analyze genetic information, ultimately guiding them in prescribing the right medications tailored to each patient's unique genetic profile. This approach enhances treatment efficacy and patient outcomes in behavioral health and other medical contexts.

Airway Therapeutics, Inc. is a biopharmaceutical company focused on developing protein therapeutics for lung and pediatric applications. Based in Cincinnati, Ohio, with additional offices in Marietta, Georgia, the company specializes in products like recombinant human surfactant protein-D, aimed at preventing bronchopulmonary dysplasia in premature infants, and AT100, a protein replacement therapy for the same condition. The company licenses technology from the pulmonary research program of Cincinnati Children's Hospital Medical Center, which supports the development of multiple products targeting various lung disorders. Airway Therapeutics aims to address the cycle of injury and inflammation in patients with respiratory and inflammatory diseases through advanced biologics that reduce inflammation, infection, and modulate immune responses, ultimately improving treatment outcomes.

AssureRX Health is a personalized medicine company based in Mason, Ohio, specializing in pharmacogenomics. The company aims to assist healthcare providers in identifying the most suitable medications for individual patients suffering from neuropsychiatric and chronic pain conditions. By offering treatment decision support, AssureRX Health enables clinicians to collect and analyze genetic information, ultimately guiding them in prescribing the right medications tailored to each patient's unique genetic profile. This approach enhances treatment efficacy and patient outcomes in behavioral health and other medical contexts.

QI Healthcare offers a suite of quality-improvement software products that enable hospitals to improve outcomes and efficiency.